Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15228358 | 0.95 | CA1 (0.38) | CA1CA9SMN1; SMN2MEN1KMT2A | |
| SCHEMBL34143 | 0.82 | — | — | |
| SCHEMBL14028822 | 0.82 | — | — | |
| SCHEMBL9305420 | 0.82 | — | — | |
| SCHEMBL15195848 | 0.81 | CA1 (0.41) | CA1CA9SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15034 | 0.81 | CA1 (0.41) | CA1CA9SMN1; SMN2MEN1KMT2A | |
| SCHEMBL44996 | 0.81 | CA1 (0.41) | CA1CA9SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2860232 | 0.81 | CA1 (0.41) | CA1CA9SMN1; SMN2MEN1KMT2A | |
| SCHEMBL8104271 | 0.81 | CA1 (0.41) | CA1CA9SMN1; SMN2MEN1KMT2A | |
| SCHEMBL732959 | 0.81 | CA1 (0.41) | CA1CA9SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3448360-B1 | BIODEGRADABLE POLYMER MICROSPHERE COMPOSITIONS FOR PARENTERAL ADMINISTRATION | ADARE PHARMACEUTICALS USA INC (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4637856-B1 | VASCULAR SCAFFOLD HAVING A RARE-EARTH METAL RADIOPAQUE MARKER | MEKO MFG E K (DE) | 2026-02-25 | — | — | EP | claimed |
| US-20260034056-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OCULAR DISEASES OR DISORDERS | ALCON INC (CH) | 2026-02-05 | — | — | US | claimed |
| EP-3562526-B1 | STENT MADE OF A BIODEGRADABLE MAGNESIUM ALLOY WITH A MAGNESIUM FLUORIDE COATING AND AN ORGANIC COATING | MEKO MFG E K (DE) | 2025-11-12 | — | — | EP | claimed |
| EP-3452124-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-10-08 | — | — | EP | claimed |
| EP-3452123-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-09-24 | — | — | EP | claimed |
| US-12403220-B2 | Scaffolds for cartilage regeneration and method for treatment of cartilage defects using the same | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) | 2025-09-02 | — | — | US | claimed |
| EP-4031108-B1 | EXTRUDED DEPOT FORM FOR CONTROLLED ACTIVE SUBSTANCE RELEASE | AMW GMBH (DE) | 2025-04-02 | — | — | EP | claimed |
| CN-114870254-B | Fully degradable electric stimulation system and preparation method thereof | 北京理工大学 | 2025-01-24 | — | — | CN | claimed |
| US-12194044-B2 | Organic compounds | 1NTRA-CELLULAR THERAP1ES, 1NC. (US) | 2025-01-14 | — | — | US | claimed |
| CN-1382108-A | Microbiological water filter | WATERVISIONS INTERNAT INC (US) | 2002-11-27 | — | — | CN | claimed |
| CN-1330536-A | Biodegradable polymer encapsulated 5-hydroxytryptamine receptor antagonists and methods of making the same | AVENTIS PHARMA INC (US) | 2002-01-09 | — | — | CN | claimed |
| EP-0854731-A1 | COPOLYMERIC MICELLE DRUG COMPOSITION AND METHOD FOR THE PREPARATION THEREOF | Sam Yang Co., Ltd. (KR) | 1998-07-29 | — | — | EP | claimed |
| WO-1997010849-A1 | COPOLYMERIC MICELLE DRUG COMPOSITION AND METHOD FOR THE PREPARATION THEREOF | SAM YANG CO., LTD. (KR) | 1997-03-27 | — | — | WO | claimed |
| EP-0720478-A1 | A CONTROLLED, SUSTAINED RELEASE DELIVERY SYSTEM FOR SMOKING CESSATION | DYNAGEN, INC. (US) | 1996-07-10 | — | — | EP | claimed |
| US-5486362-A | Controlled, sustained release delivery system for treating drug dependency | DYNAGEN, INC. (US) | 1996-01-23 | — | — | US | claimed |
| EP-0349127-B1 | ANTIBODY-MEDIATED AND LIGAND-MEDIATED TARGETING OF DIFFERENTIATION-INDUCERS TO TUMOR CELLS | The Biomembrane Institute (US) | 1993-09-29 | — | — | EP | claimed |
| WO-1992019226-A1 | A CONTROLLED, SUSTAINED RELEASE DELIVERY SYSTEM FOR TREATING DRUG DEPENDENCY | DYNAGEN, INC. (US) | 1992-11-12 | — | — | WO | claimed |
| WO-1992019241-A1 | A CONTROLLED, SUSTAINED RELEASE DELIVERY SYSTEM FOR SMOKING CESSATION | DYNAGEN, INC. (US) | 1992-11-12 | — | — | WO | claimed |
| EP-0349127-A1 | Antibody-mediated and ligand-mediated targeting of differentiation-inducers to tumor cells | The Biomembrane Institute (US) | 1990-01-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12194044-B2 | Organic compounds | HTR2C, HTR2A, HTR1A | CA1 3357/4885CA9 4284/4885SMN1; SMN2 1684/4885 |
| US-20260034056-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OCULAR DISEASES OR DISORDERS | KDR, FLT4, FLT1 | CA1 4363/4885CA9 1841/4885SMN1; SMN2 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.